The study is a 24-week prospective, double blind, randomized, placebo-controlled pilot study
of 9 mg / day Rivastigmine in patients with Vascular Cognitive Impairment Not Dementia (CIND)
to evaluate efficacy, safety and tolerability in Asian patients. The hypothesis is that
patients receiving Rivastigmine would improve in executive functioning domains.